CN1312071A - Linolic acid and linolenic acid capsule and its making process - Google Patents
Linolic acid and linolenic acid capsule and its making process Download PDFInfo
- Publication number
- CN1312071A CN1312071A CN 01106094 CN01106094A CN1312071A CN 1312071 A CN1312071 A CN 1312071A CN 01106094 CN01106094 CN 01106094 CN 01106094 A CN01106094 A CN 01106094A CN 1312071 A CN1312071 A CN 1312071A
- Authority
- CN
- China
- Prior art keywords
- acid
- linolenic acid
- capsule
- alpha
- linolic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 title claims abstract description 84
- 235000020661 alpha-linolenic acid Nutrition 0.000 title claims abstract description 56
- 229960004488 linolenic acid Drugs 0.000 title claims abstract description 56
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 title claims abstract description 55
- 229960004232 linoleic acid Drugs 0.000 title claims abstract description 55
- 239000002775 capsule Substances 0.000 title claims abstract description 35
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims description 19
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000003813 safflower oil Substances 0.000 claims abstract description 32
- 235000020778 linoleic acid Nutrition 0.000 claims abstract description 28
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 28
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 21
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 21
- 229940046009 vitamin E Drugs 0.000 claims abstract description 21
- 239000011709 vitamin E Substances 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 235000019485 Safflower oil Nutrition 0.000 claims description 31
- 235000005713 safflower oil Nutrition 0.000 claims description 31
- 239000003921 oil Substances 0.000 claims description 23
- 235000019198 oils Nutrition 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 239000007901 soft capsule Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 16
- 239000008280 blood Substances 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 13
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 11
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 9
- 235000012000 cholesterol Nutrition 0.000 abstract description 7
- 230000015654 memory Effects 0.000 abstract description 7
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract 1
- 235000021388 linseed oil Nutrition 0.000 abstract 1
- 239000000944 linseed oil Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 10
- 206010010774 Constipation Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000036541 health Effects 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- ADHNUPOJJCKWRT-JLXBFWJWSA-N (2e,4e)-octadeca-2,4-dienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C(O)=O ADHNUPOJJCKWRT-JLXBFWJWSA-N 0.000 description 1
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical group CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004793 poor memory Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a linolenic acid linoleic acid capsule and its preparation method. Said invention uses safflower seed oil in which the contained linoleic acid content is 74-84% and linseed oil in which the contained alpha-linolenic acid content is 45-50% and medical vitamin E as raw material. According to the weight ratio of 100:169-338, the medical vitamin E whose content is 0.5-1.0% of total weight of its prescription can be added to make the ratio of effective components of alpha-linolenic acid and linoleic acid of said medicine be 1:2.5-6.3. Said medicine possesses the functions of reducing cholesterol in blood, triglyceride and low-density lipoprotein, raising high-density protein, preventing atheroma, improving cardio-cerebral vessel and raising memory, etc.
Description
The medicine that the present invention relates to keep healthy preparation is meant blood fat reducing brain-strengthening health medicine and preparation thereof especially.
Along with the raising of people's living standard, the people of hyperlipidemia is more and more, the blood fat chemical examination, T-CHOL, triglyceride and low density lipoprotein, LDL raise or the high density lipoprotein reduction all can be described as hyperlipemia, and these compositions of T-CHOL, triglyceride and low density lipoprotein, LDL are mixed in the blood, just as the silt in the river, at any time be deposited on the blood vessel wall, and in the intrusion blood vessel wall, adding other factors, the part can form speckle, lumen of vessels is narrowed down, the blood vessel wall thickening follows the string, and forms arteriosclerosis.Arteries is distributed in all organs of health, and these organs all can be got involved because of arteriosclerosis, cause diseases such as angina pectoris, myocardial infarction, cerebral arteriosclerosis, cerebral hemorrhage, apoplexy.The lipid lowerers of determined curative effect mainly contains two big classes, i.e. the special class of his class D (simvastatin, fluvastatin and atorvastatin etc.) and shellfish.These synthetic drugs, life-time service has side effect, and therapeutic effect is not remarkable.Brain-strengthening health care medicine is also a lot of in addition, and brain-strengthening health care medicine is started with from different perspectives, plays brain-strengthening, and the memory reinforcing effect is not also with the health care medicine of blood fat reducing and cerebral tonic mixed preparing.
The purpose of this invention is to provide a kind of blood fat reducing brain-strengthening, prevention of arterial is atherosis, improves cardiovascular and cerebrovascular vessel, the linolic acid and linolenic acid capsule of memory reinforcing and method for making thereof.
The object of the present invention is achieved like this, and the linolic acid and linolenic acid capsule effective component is: alpha-linolenic acid: linoleic acid=1: 2.5～6.3.Dosage form is a capsule.
The method for making of linolic acid and linolenic acid capsule is:
The first step: select the safflower oil that contains linoleic acid 74～84% for use, contain the Semen Lini oil and the medicinal vitamin E of alpha-linolenic acid 45～50%, weigh up by the prescription weight ratio.Weight ratio is:
Semen Lini oil: safflower oil=100: 169～338
Weigh up the medicinal vitamin E that accounts for prescription gross weight 0.5～1.0% again.
Second the step: with vitamin E be dissolved in the safflower oil total amount 1/3 in, stir, add in the material-compound tank then.
The 3rd step: while stirring under the condition of nitrogen, nitrogen pressure is that 0.1～0.5Pa adds safflower oil in the material-compound tank, stirs.
The net step: in the safflower oil in the Semen Lini oil adding stirring, continue to stir 20～30 minutes.
The 5th step: get sample, chemical examination is satisfied alpha-linolenic acid: linoleic acid=1: 2.5～6.3.
The 6th step: soft capsule preparation.Capsule 's content 0.5g/ grain.
Through the linolic acid and linolenic acid capsule that said method makes, mouthfeel is good, and instructions of taking is: each 3～5, and twice of every day.
Linolic acid and linolenic acid capsule effective component preferable range is: alpha-linolenic acid: linoleic acid=1: 2.5～3.8.
The method for making preferable range of linolic acid and linolenic acid capsule is:
The safflower oil that contains linoleic acid 74～84% contains the Semen Lini oil and the medicinal vitamin E of alpha-linolenic acid 45～50%, and weight ratio is: Semen Lini oil: safflower oil=100: 169～203.
Advantage of the present invention is: both claim essential fatty acid alpha-linolenic acid (chemical name is a jeceric acid) and linoleic acid (chemical name octadecadienoic acid) on biochemistry, human body self can not synthesize, must be by food supply, safflower oil is rich in linoleic acid, linoleic acid has the blood cholesterol of reduction, triglyceride, low density lipoprotein, LDL, increase the effect of high-density protein, phospholipid is not had influence.Semen Lini oil is rich in alpha-linolenic acid, but alpha-linolenic acid metabolic conversion in human body is eicosapentaenoic acid and the docosahexenoic acid that is commonly called as NAOHUANGJIN, has the function that activates the brain cell improving memory.According to the requirement of the person to these two kinds of unsaturated fatty acids, scientific composition is had complementary advantages, coordinative role, and edible back is directly absorbed by human body.Two of effects are obviously complementary, have no side effect, and play blood fat reducing, and improving memory is very favourable to preventing senile cardiovascular disease and dementia.Production technology is simple relatively, and is with low cost, is beneficial to and applies.
The present invention is described in detail below in conjunction with embodiment.
Embodiment 1
The method for making of linolic acid and linolenic acid capsule:
The first step: selecting linoleic acid content for use is 74% safflower oil, and selecting alpha-linolenic acid content for use is 45% Semen Lini oil, the drug of choice vitamin E.Weigh up by the prescription weight ratio.Weight ratio is:
Semen Lini oil: safflower oil=100: 169.
Weigh up the medicinal vitamin E that accounts for prescription gross weight 0.5% again.
Second the step: with vitamin E be dissolved in the safflower oil total amount 1/3 in, stir, add in the material-compound tank then.
The 3rd step: while stirring under the condition of nitrogen, nitrogen pressure is 0.1Pa, and safflower oil is added in the material-compound tank, stirs.
The 4th step: in the safflower oil in the Semen Lini oil adding stirring, continue to stir 20 minutes.
The 5th step: get the sample chemical examination and learn:
Alpha-linolenic acid: linoleic acid=1: 2.5
The 6th step: soft capsule preparation, capsule 's content are the 0.5g/ grain.
The linolic acid and linolenic acid capsule effective component that makes through said method is:
Alpha-linolenic acid: linoleic acid=1: 2.5.
Model case: man, 37 years old, government functionary, obesity, serum triglycerides height (4.56mmol/L, normal value is in 2), dizziness, lethargy, weak, hypomnesis.Take one week of capsule, symptom is improved, and chemically examines after January, and triglyceride is reduced to 2.34mmol/L, loses weight 5 kilograms, and constipation disappears.
Embodiment 2
The method for making of linolic acid and linolenic acid capsule:
The first step is selected the safflower oil that contains linoleic acid 84% for use, contains the Semen Lini oil and the medicinal vitamin E of alpha-linolenic acid 45%.Weigh up by the prescription weight ratio.Weight ratio is:
Semen Lini oil: safflower oil=100: 203.
Weigh up the medicinal vitamin E that accounts for prescription gross weight 1% again.
Second the step: with vitamin E be dissolved in the safflower oil total amount 1/3 in, stir, add in the material-compound tank then.
The 3rd step: while stirring under the condition of nitrogen, nitrogen pressure is 0.3Pa, and safflower oil is added in the material-compound tank, stirs.
The 4th step: in the safflower oil in the Semen Lini oil adding stirring, continue to stir 25 minutes.
The 5th step: get sample, chemical examination is learnt.
Alpha-linolenic acid: linoleic acid=1: 3.8.
The 6th step: soft capsule preparation, capsule 's content are the 0.5g/ grain.
The linolic acid and linolenic acid capsule effective component that makes through said method is:
Alpha-linolenic acid: linoleic acid=1: 3.8.
Bent type case: woman, 55 years old, engineer, self-induction dizziness headache uncomfortable in chest before taking has the constipation phenomenon, health check-up cholesterol 8.1mmol/L once in a while, be hypercholesterolemia, two months no positive effects of treatment by Chinese herbs are taken above-mentioned one week of medicine, and subjective symptoms alleviates, condition of illness greatly all improves after January, cholesterol drops to 6.8mmol/L, and condition of illness disappears after March, and cholesterol is reduced to normally.
Embodiment 3
The method for making of linolic acid and linolenic acid capsule.
The first step: select the safflower oil that contains linoleic acid 84% for use, contain the Semen Lini oil and the medicinal vitamin E of alpha-linolenic acid 50%, weigh up by the prescription weight ratio.Weight ratio is:
Semen Lini oil: safflower oil=100: 179
Weigh up the medicinal vitamin E that accounts for prescription gross weight 1.0% again.
Second to the 4th step and the 6th step are identical with embodiment 1.
The 5th step: get the sample chemical examination and learn.
Alpha-linolenic acid: linoleic acid=1: 3
The linolic acid and linolenic acid capsule effective component that makes through said method is:
Alpha-linolenic acid: linoleic acid=1: 3.
Carry out clinical experiment, laboratory report is as follows: crowd 60 people in 35-80 year have carried out the clinical experiment of linolic acid and linolenic acid capsule to the age.Being divided into three groups, is foundation with clinical blood fat result of laboratory test, and hypercholesterolemia, the higher constipation person of having concurrently of glyceride are first group; It is second group that triglyceride height, cholesterol substantially normally have constipation person concurrently; The blood fat chemical examination is normal, has slight constipation person to be matched group.The people of experimental group exists hyperlipidemia symptoms such as dizziness, weak, insobriety poor memory to some extent.Dose: take the 6-10 grain for each person every day; 6 of matched group (20 people) every days, took continuously 3 months.Observing effect: a, invalid: the user feels symptom and does not disappear, and memory not to be improved, and constipation is to no effect; B, effectively: the user feels clearheaded, and memory increases, freedom of movement, constipation is eliminated; C, produce effects: the user is except that the sensation that b is arranged, and clinical blood fat is chemically examined visible gallbladder with alcohol, triglyceride obviously descend (normal or near normal value).The result is as follows: experimental group number of participant dose effect (number)
(grain) a b c experimental group 1 20 6-10-20 19 experimental group 2 20 6-10-20 17 matched group 20 6-10
*-
*It is constipation person that 10 people are arranged in the matched group; * blood fat chemical examination normal range as can be known from the table data: experimental group effectively reaches 100%; Obvious effective rate reaches 90%; To not influence of normal lipid, be 100% to constipation person's effective percentage.
Embodiment 4
The method for making of linolic acid and linolenic acid capsule.
The first step: select the safflower oil that contains linoleic acid 84% for use, contain the Semen Lini oil and the medicinal vitamin E of alpha-linolenic acid 45%, weigh up by the prescription weight ratio, weight ratio is:
Semen Lini oil: safflower oil=100: 338
Weigh up the medicinal vitamin E that accounts for prescription gross weight 0.8% again.
Second to the 4th step and the 6th step are identical with embodiment 1.
The 5th step: get the sample chemical examination and learn.
Alpha-linolenic acid: linoleic acid=1: 6.3
The linolic acid and linolenic acid capsule effective component that makes through said method is:
Alpha-linolenic acid: linoleic acid=1: 6.3
Bent type case: the woman, 61 years old, the Uygur nationality, obesity, hyperlipidemia, hypertension, take capsule before and after (three months) blood fat result of laboratory test as follows:
After taking before inspection item is taken
Cholesterol ch 7.79mmol/L 4.34mmol/L
Triglyceride TG 1.94mmol/L 1.06mmol/L
High density lipoprotein HDL-c 1.20mmol/L 1.28mmol/L
Low density lipoprotein, LDL is at LDL-c 5.78mmol/L 2.32mmol/L
Drop to normal and near normal, triglyceride slightly descends from the visible cholesterol of analysis data and low density lipoprotein, LDL, high density lipoprotein has rising trend.
Claims (6)
1, linolic acid and linolenic acid capsule is characterized in that: the linolic acid and linolenic acid capsule effective component is: alpha-linolenic acid: linoleic acid=1: 2.5～6.3.
2, linolic acid and linolenic acid capsule according to claim 1 is characterized in that: linolic acid and linolenic acid capsule effective component preferable range is: alpha-linolenic acid: linoleic acid=1: 2.5～3.8.
3, linolic acid and linolenic acid capsule according to claim 1 is characterized in that: dosage form is a capsule.
4, the method for making of linolic acid and linolenic acid capsule is characterized in that:
The first step: select the safflower oil that contains linoleic acid 74～84% for use, contain the Semen Lini oil and the medicinal vitamin E of alpha-linolenic acid 45～50%, weigh up by the prescription weight ratio, weight ratio is:
Semen Lini oil: safflower oil=100: 169～338
Weigh up the medicinal vitamin E that accounts for prescription gross weight 0.5～1.0% again;
Second the step: with vitamin E be dissolved in the safflower oil total amount 1/3 in, stir, add then in the material-compound tank;
The 3rd step: while stirring under the condition of nitrogen, nitrogen pressure is 0.1～0.5Pa, and safflower oil is added in the material-compound tank, stirs;
The 4th step: in the safflower oil in the Semen Lini oil adding stirring, continue to stir 20～30 minutes;
The 5th step: get sample, chemical examination is satisfied alpha-linolenic acid: linoleic acid=1: 2.5～6.3;
The 6th step: soft capsule preparation.
5, will be according to the method for making of the described linolic acid and linolenic acid capsule of claim 3, it is characterized in that: the method for making preferable range of linolic acid and linolenic acid capsule is: the safflower oil that contains linoleic acid 74～84%, contain the Semen Lini oil and the medicinal vitamin E of alpha-linolenic acid 45～50%, the prescription weight ratio is: Semen Lini oil: safflower oil=100: 169～203.
6, will be according to the method for making of the described linolic acid and linolenic acid capsule of claim 3, it is characterized in that: the method for making preferred plan of linolic acid and linolenic acid capsule is: select the safflower oil that contains linoleic acid 84% for use, contain the Semen Lini oil and the medicinal vitamin E of alpha-linolenic acid 50%, the prescription weight ratio is: Semen Lini oil: safflower oil=100: 179.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011060948A CN1155375C (en) | 2001-01-17 | 2001-01-17 | Linolic acid and linolenic acid capsule and its making process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011060948A CN1155375C (en) | 2001-01-17 | 2001-01-17 | Linolic acid and linolenic acid capsule and its making process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1312071A true CN1312071A (en) | 2001-09-12 |
| CN1155375C CN1155375C (en) | 2004-06-30 |
Family
ID=4655146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011060948A Expired - Fee Related CN1155375C (en) | 2001-01-17 | 2001-01-17 | Linolic acid and linolenic acid capsule and its making process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1155375C (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100255126A1 (en) * | 2004-12-13 | 2010-10-07 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
| US8092839B2 (en) * | 2004-12-13 | 2012-01-10 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
| CN102356880A (en) * | 2011-10-24 | 2012-02-22 | 陈元涛 | Linseed oil microcapsule and preparation method thereof |
| CN102697046A (en) * | 2012-06-09 | 2012-10-03 | 东莞市照燕生物科技有限公司 | Dietary supplement for lowering blood lipid |
| CN102934703A (en) * | 2012-11-13 | 2013-02-20 | 中国食品发酵工业研究院 | Flaxseed oil microcapsule and production method thereof |
| CN103284151A (en) * | 2013-06-01 | 2013-09-11 | 赵全成 | Omega-3 unsaturated vegetable combined oil with effect of reducing blood fat |
| CN103493908A (en) * | 2013-10-11 | 2014-01-08 | 河南科技大学 | Nut blend oil with lipid lowering and blood glucose reducing effects and preparation method thereof |
| US8728546B1 (en) | 2013-03-15 | 2014-05-20 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer, cardiovascular diseases and inflammation |
| CN106074577A (en) * | 2016-06-30 | 2016-11-09 | 重庆帅旭科技发展有限公司 | For improving functional type alimentation composition and the application thereof of memory |
| CN106954858A (en) * | 2017-03-31 | 2017-07-18 | 广州市健鸣春生物科技有限公司 | A kind of preparation method with beautifying face and moistering lotion anti-aging, the natural VE formula added with rose oil, capsule and capsule |
| CN107232602A (en) * | 2017-06-08 | 2017-10-10 | 华子昂 | It is a kind of that there is the health food for aiding in three high drop function |
| IT201900022764A1 (en) * | 2019-12-03 | 2021-06-03 | Skb Llc | SKIN CARE PRODUCT AND PROCEDURE FOR ITS REALIZATION |
| CN112889934A (en) * | 2021-03-25 | 2021-06-04 | 张胜建 | Plant blend oil and formula method thereof |
| CN116058417A (en) * | 2022-11-25 | 2023-05-05 | 新疆札郎孜生物科技有限公司 | Vegetable blend oil and application thereof |
-
2001
- 2001-01-17 CN CNB011060948A patent/CN1155375C/en not_active Expired - Fee Related
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100255126A1 (en) * | 2004-12-13 | 2010-10-07 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
| US8092839B2 (en) * | 2004-12-13 | 2012-01-10 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
| US8431165B2 (en) * | 2004-12-13 | 2013-04-30 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
| CN102356880A (en) * | 2011-10-24 | 2012-02-22 | 陈元涛 | Linseed oil microcapsule and preparation method thereof |
| CN102356880B (en) * | 2011-10-24 | 2016-02-17 | 陈元涛 | A kind of linseed oil microcapsule and preparation method |
| CN102697046A (en) * | 2012-06-09 | 2012-10-03 | 东莞市照燕生物科技有限公司 | Dietary supplement for lowering blood lipid |
| CN102934703A (en) * | 2012-11-13 | 2013-02-20 | 中国食品发酵工业研究院 | Flaxseed oil microcapsule and production method thereof |
| CN102934703B (en) * | 2012-11-13 | 2015-07-15 | 中国食品发酵工业研究院 | Flaxseed oil microcapsule and production method thereof |
| US8728546B1 (en) | 2013-03-15 | 2014-05-20 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer, cardiovascular diseases and inflammation |
| CN103284151A (en) * | 2013-06-01 | 2013-09-11 | 赵全成 | Omega-3 unsaturated vegetable combined oil with effect of reducing blood fat |
| CN103493908A (en) * | 2013-10-11 | 2014-01-08 | 河南科技大学 | Nut blend oil with lipid lowering and blood glucose reducing effects and preparation method thereof |
| CN106074577A (en) * | 2016-06-30 | 2016-11-09 | 重庆帅旭科技发展有限公司 | For improving functional type alimentation composition and the application thereof of memory |
| CN106954858A (en) * | 2017-03-31 | 2017-07-18 | 广州市健鸣春生物科技有限公司 | A kind of preparation method with beautifying face and moistering lotion anti-aging, the natural VE formula added with rose oil, capsule and capsule |
| CN107232602A (en) * | 2017-06-08 | 2017-10-10 | 华子昂 | It is a kind of that there is the health food for aiding in three high drop function |
| IT201900022764A1 (en) * | 2019-12-03 | 2021-06-03 | Skb Llc | SKIN CARE PRODUCT AND PROCEDURE FOR ITS REALIZATION |
| CN112889934A (en) * | 2021-03-25 | 2021-06-04 | 张胜建 | Plant blend oil and formula method thereof |
| CN116058417A (en) * | 2022-11-25 | 2023-05-05 | 新疆札郎孜生物科技有限公司 | Vegetable blend oil and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1155375C (en) | 2004-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1155375C (en) | Linolic acid and linolenic acid capsule and its making process | |
| CN1756545A (en) | Use of omega-3-fatty acids in the treatment of diabetic patients | |
| JP2011501667A (en) | Composition for controlling lipid metabolism | |
| CN102228241A (en) | Health-care food capable of tonifying brain, enhancing intelligence and enhancing memory and preparation method thereof | |
| CN1579180A (en) | Mixed safflower oil | |
| CN103169765A (en) | Eucommia ulmoides seed oil and red rice compound soft capsule preparation and preparation method thereof | |
| CN1421208A (en) | Compound prepn containing alpha-linolic acid, lecithin and ginkgetin | |
| CN1104252C (en) | Health-care oil for reducing cholesterol and its preparing process | |
| CN1114878A (en) | Preparation of prevention and cure of cardio-vascular diseases | |
| CN1262284C (en) | Health care product of hippophae rhamnoides oil | |
| CN103690821B (en) | A kind of auxiliary antilipemic compositions | |
| CN102106534A (en) | Composition for assisting in lowering blood fat and preparation method thereof | |
| CN109527579A (en) | A kind of application of surprise Asia seed oil product and preparation method thereof and the sub- seed oil product of the surprise | |
| CN1122528C (en) | Composite safflower oil preparation and medicine containing it | |
| CN1201611A (en) | Health food macte from cereal, vegetable and fruit | |
| CN102205010A (en) | Pharmaceutical composition with auxiliary function of reducing blood fat | |
| CN1923227A (en) | Traditional Chinese medicinal formulation for treating ischemic cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN105707568A (en) | Alpha-linolenic acid soft capsule with function of auxiliarily lowering blood lipids and preparation method thereof | |
| CN1247761C (en) | Health-care strengthening-nourishing solution | |
| CN1207036C (en) | Traditional Chinese medicine formule for treating hyperlipemia | |
| CN1251684C (en) | Health care food for relaxing hypertension | |
| CN109528827A (en) | A kind of promoting blood circulation, reducing blood lipid, the pharmaceutical composition of auxiliary adjustment cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN1176820A (en) | Red ginseng and hawthorn fruit health-care wine | |
| CN1973686A (en) | Natural beverage liquid with functions of lowering cholesterol and regulating blood fat and its prepn process | |
| CN1943613A (en) | Granular agent with brain strengthening function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |